Denali Therapeutics Inc. (DNLI): Capital Expenditures
$9.50M
Year ended 2025-12-31
$3.42M
Trailing 12 months to 2026-06-30
-18.9%
3-year compound annual growth
+25.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.50M | -40.3% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $15.91M | +23.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $12.94M | -27.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $17.83M | +109.8% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $8.50M | +174.6% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $3.10M | -82.7% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $17.92M | +428.1% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $3.39M | +18.0% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $2.88M | -53.1% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $6.13M | n/a | 2019-03-12, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $9.50M | -40.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $1.86B | +69.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $563.00M | +7.6% |
Compare DNLI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗